Neurocrine Biosciences Inc (NBIX) - Net Assets
Based on the latest financial reports, Neurocrine Biosciences Inc (NBIX) has net assets worth $3.25 Billion USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.63 Billion) and total liabilities ($1.38 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Neurocrine Biosciences Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.25 Billion |
| % of Total Assets | 70.24% |
| Annual Growth Rate | 14.0% |
| 5-Year Change | 136.76% |
| 10-Year Change | 933.13% |
| Growth Volatility | 90.97 |
Neurocrine Biosciences Inc - Net Assets Trend (1996–2025)
This chart illustrates how Neurocrine Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore Neurocrine Biosciences Inc asset portfolio for the complete picture of this company's asset base.
Annual Net Assets for Neurocrine Biosciences Inc (1996–2025)
The table below shows the annual net assets of Neurocrine Biosciences Inc from 1996 to 2025. For live valuation and market cap data, see how much is Neurocrine Biosciences Inc worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.25 Billion | +25.62% |
| 2024-12-31 | $2.59 Billion | +16.03% |
| 2023-12-31 | $2.23 Billion | +30.69% |
| 2022-12-31 | $1.71 Billion | +24.29% |
| 2021-12-31 | $1.37 Billion | +22.00% |
| 2020-12-31 | $1.13 Billion | +76.83% |
| 2019-12-31 | $636.90 Million | +32.48% |
| 2018-12-31 | $480.76 Million | +29.19% |
| 2017-12-31 | $372.14 Million | +18.19% |
| 2016-12-31 | $314.88 Million | -25.82% |
| 2015-12-31 | $424.45 Million | +103.38% |
| 2014-12-31 | $208.70 Million | +73.32% |
| 2013-12-31 | $120.41 Million | -22.00% |
| 2012-12-31 | $154.37 Million | +156.94% |
| 2011-12-31 | $60.08 Million | +210.58% |
| 2010-12-31 | $19.34 Million | +389.25% |
| 2009-12-31 | $3.95 Million | -89.25% |
| 2008-12-31 | $36.77 Million | -69.02% |
| 2007-12-31 | $118.70 Million | -62.28% |
| 2006-12-31 | $314.72 Million | -19.33% |
| 2005-12-31 | $390.10 Million | -0.95% |
| 2004-12-31 | $393.83 Million | +0.69% |
| 2003-12-31 | $391.12 Million | +74.41% |
| 2002-12-31 | $224.25 Million | -27.75% |
| 2001-12-31 | $310.39 Million | +90.18% |
| 2000-12-31 | $163.21 Million | +69.30% |
| 1999-12-31 | $96.40 Million | +33.89% |
| 1998-12-31 | $72.00 Million | -13.46% |
| 1997-12-31 | $83.20 Million | +14.29% |
| 1996-12-31 | $72.80 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neurocrine Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 45770000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $447.70 Million | 13.76% |
| Common Stock | $100.00K | 0.00% |
| Other Comprehensive Income | $13.10 Million | 0.40% |
| Other Components | $2.79 Billion | 85.83% |
| Total Equity | $3.25 Billion | 100.00% |
Neurocrine Biosciences Inc Competitors by Market Cap
The table below lists competitors of Neurocrine Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Investment AB Latour (publ)
ST:LATO-B
|
$13.05 Billion |
|
Toll Brothers Inc
NYSE:TOL
|
$13.06 Billion |
|
Coloplast A/S
CO:COLO-B
|
$13.06 Billion |
|
IGM Financial Inc.
TO:IGM
|
$13.07 Billion |
|
NESTE OYJ UNSP.ADR 1/2
F:NEFA
|
$13.02 Billion |
|
Shengyi Electronics Co. Ltd. A
SHG:688183
|
$13.01 Billion |
|
Sterling Construction Company Inc
NASDAQ:STRL
|
$12.99 Billion |
|
Advantech Co Ltd
TW:2395
|
$12.99 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neurocrine Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,589,700,000 to 3,253,100,000, a change of 663,400,000 (25.6%).
- Net income of 478,600,000 contributed positively to equity growth.
- Share repurchases of 167,700,000 reduced equity.
- Other comprehensive income increased equity by 7,300,000.
- Other factors increased equity by 345,200,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $478.60 Million | +14.71% |
| Share Repurchases | $167.70 Million | -5.16% |
| Other Comprehensive Income | $7.30 Million | +0.22% |
| Other Changes | $345.20 Million | +10.61% |
| Total Change | $- | 25.62% |
Book Value vs Market Value Analysis
This analysis compares Neurocrine Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.80x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 34.27x to 4.80x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1996-12-31 | $4.44 | $152.25 | x |
| 1997-12-31 | $4.57 | $152.25 | x |
| 1998-12-31 | $3.97 | $152.25 | x |
| 1999-12-31 | $5.05 | $152.25 | x |
| 2000-12-31 | $7.38 | $152.25 | x |
| 2001-12-31 | $11.93 | $152.25 | x |
| 2002-12-31 | $7.36 | $152.25 | x |
| 2003-12-31 | $12.08 | $152.25 | x |
| 2004-12-31 | $10.88 | $152.25 | x |
| 2005-12-31 | $10.27 | $152.25 | x |
| 2006-12-31 | $8.34 | $152.25 | x |
| 2007-12-31 | $3.12 | $152.25 | x |
| 2008-12-31 | $0.96 | $152.25 | x |
| 2009-12-31 | $0.10 | $152.25 | x |
| 2010-12-31 | $0.37 | $152.25 | x |
| 2011-12-31 | $1.07 | $152.25 | x |
| 2012-12-31 | $2.31 | $152.25 | x |
| 2013-12-31 | $1.80 | $152.25 | x |
| 2014-12-31 | $2.80 | $152.25 | x |
| 2015-12-31 | $5.02 | $152.25 | x |
| 2016-12-31 | $3.63 | $152.25 | x |
| 2017-12-31 | $4.22 | $152.25 | x |
| 2018-12-31 | $5.04 | $152.25 | x |
| 2019-12-31 | $6.65 | $152.25 | x |
| 2020-12-31 | $11.52 | $152.25 | x |
| 2021-12-31 | $14.03 | $152.25 | x |
| 2022-12-31 | $17.27 | $152.25 | x |
| 2023-12-31 | $22.10 | $152.25 | x |
| 2024-12-31 | $24.97 | $152.25 | x |
| 2025-12-31 | $31.74 | $152.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neurocrine Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 14.71%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.73%
- • Asset Turnover: 0.62x
- • Equity Multiplier: 1.42x
- Recent ROE (14.71%) is above the historical average (-63.80%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1996 | 8.10% | 30.73% | 0.25x | 1.07x | $-1.38 Million |
| 1997 | 6.13% | 19.54% | 0.28x | 1.10x | $-3.22 Million |
| 1998 | -27.78% | -125.00% | 0.20x | 1.12x | $-27.20 Million |
| 1999 | -17.43% | -100.00% | 0.15x | 1.13x | $-26.44 Million |
| 2000 | -17.65% | -197.48% | 0.08x | 1.14x | $-45.13 Million |
| 2001 | -11.89% | -89.50% | 0.12x | 1.12x | $-67.95 Million |
| 2002 | -42.16% | -523.89% | 0.07x | 1.19x | $-116.96 Million |
| 2003 | -7.74% | -21.75% | 0.25x | 1.42x | $-69.37 Million |
| 2004 | -11.62% | -53.74% | 0.16x | 1.32x | $-85.16 Million |
| 2005 | -5.69% | -17.91% | 0.26x | 1.24x | $-61.20 Million |
| 2006 | -34.06% | -273.25% | 0.10x | 1.24x | $-138.68 Million |
| 2007 | -174.65% | -16936.19% | 0.00x | 2.33x | $-219.17 Million |
| 2008 | -240.97% | -2229.26% | 0.03x | 3.21x | $-92.29 Million |
| 2009 | -1290.79% | -1728.34% | 0.04x | 17.91x | $-51.43 Million |
| 2010 | -41.19% | -23.78% | 0.23x | 7.47x | $-9.90 Million |
| 2011 | 62.53% | 48.53% | 0.56x | 2.30x | $31.56 Million |
| 2012 | 3.26% | 9.46% | 0.27x | 1.27x | $-10.41 Million |
| 2013 | -38.28% | -1578.97% | 0.02x | 1.28x | $-58.13 Million |
| 2014 | -29.01% | 0.00% | 0.00x | 1.16x | $-81.41 Million |
| 2015 | -20.95% | -449.84% | 0.04x | 1.12x | $-131.37 Million |
| 2016 | -44.81% | -940.60% | 0.04x | 1.16x | $-172.58 Million |
| 2017 | -38.30% | -88.19% | 0.20x | 2.20x | $-179.76 Million |
| 2018 | 4.39% | 4.68% | 0.45x | 2.07x | $-26.97 Million |
| 2019 | 5.81% | 4.69% | 0.60x | 2.05x | $-26.69 Million |
| 2020 | 36.17% | 38.94% | 0.60x | 1.54x | $294.68 Million |
| 2021 | 6.52% | 7.90% | 0.55x | 1.51x | $-47.80 Million |
| 2022 | 9.05% | 10.38% | 0.63x | 1.39x | $-16.28 Million |
| 2023 | 11.19% | 13.23% | 0.58x | 1.46x | $26.50 Million |
| 2024 | 13.18% | 14.49% | 0.63x | 1.44x | $82.33 Million |
| 2025 | 14.71% | 16.73% | 0.62x | 1.42x | $153.29 Million |
Industry Comparison
This section compares Neurocrine Biosciences Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $228,431,275
- Average return on equity (ROE) among peers: -34.82%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neurocrine Biosciences Inc (NBIX) | $3.25 Billion | 8.10% | 0.42x | $13.03 Billion |
| Aurora Cannabis Inc (ACB) | $605.09 Million | 0.26% | 0.40x | $193.38 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $30.76 Million | -42.81% | 0.13x | $310.74 Million |
| Alkermes Plc (ALKS) | $79.15 Million | -15.90% | 0.32x | $4.62 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $340.61 Million | -58.24% | 0.15x | $1.63 Billion |
| Amphastar P (AMPH) | $251.54 Million | 4.72% | 0.35x | $862.03 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $356.74 Million | 25.53% | 10.23x | $3.81 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $263.49 Million | 12.07% | 0.07x | $197.93 Million |
| ANI Pharmaceuticals Inc (ANIP) | $15.83 Million | -300.23% | 1.30x | $1.80 Billion |
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESS… Read more